Santoro Antonio
Division of Nephrology and Dialysis Policlinico S. Orsola-Malpighi, Bologna, Italy.
Rev Clin Exp Hematol. 2002;Suppl 1:12-20.
In renal failure, severe anemia and associated fatigue, cognitive and sexual dysfunction have a significant impact on the patient's quality of life. Anemia has also been identified as an important etiologic factor in the development of left ventricular hypertrophy. The major cause of anemia in presence of a reduction of glomerular filtration rate is an inadequate production of a glycoprotein hormone, the erythropoietin (EPO). EPO is the primary regulator of the growth and survival of erythroid progenitor. The introduction of recombinant human erythropoietin (rHuEPO) has revolutionized the treatment of anemia in chronic renal failure. The vast majority of patients respond very well to treatment, but 5-10% of patients show some resistance to EPO, the most common cause of which is iron deficiency. Several studies are recently commenced to investigate the effects of preventing renal anemia ever developing. The target of hemoglobin concentration in pre-dialysis and dialysis patients are object of continuous re-examinations.
在肾衰竭中，严重贫血以及相关的疲劳、认知和性功能障碍对患者的生活质量有重大影响。贫血也被认为是左心室肥厚发展的一个重要病因。肾小球滤过率降低时贫血的主要原因是一种糖蛋白激素——促红细胞生成素（EPO）产生不足。EPO是红系祖细胞生长和存活的主要调节因子。重组人促红细胞生成素（rHuEPO）的引入彻底改变了慢性肾衰竭贫血的治疗方法。绝大多数患者对治疗反应良好，但5% - 10%的患者对EPO有一定抵抗，最常见的原因是缺铁。最近开展了几项研究来调查预防肾性贫血发生的效果。透析前和透析患者血红蛋白浓度的目标是持续重新审视的对象。
